Іпілімумаб (Ukrainian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Іпілімумаб" in Ukrainian language version.

refsWebsite

Global rank Ukrainian rank

22nih.gov

4^th place

5^th place

17doi.org

2^nd place

4^th place

5fda.gov

447^th place

906^th place

4web.archive.org

1^st place

3books.google.com

3^rd place

11^th place

3archive.org

6^th place

3harvard.edu

18^th place

74^th place

1biocentury.com

low place

1ama-assn.org

3,257^th place

6,919^th place

1medscape.com

719^th place

441^st place

1sanofi.com.au

low place

1gene.com

low place

1bms.com

low place

1europa.eu

68^th place

77^th place

ama-assn.org

USAN. STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL - ipilimumab (Пресреліз). American Medical Association (AMA). Архів оригіналу за 23 лютого 2016. Процитовано 12 січня 2013.

archive.org

Invasion of the Prostate Snatchers: No More Unnecessary Biopsies, Radical Treatment Or Loss of Sexual Potency. Other Press, LLC. 24 серпня 2010. с. 227–. ISBN 978-1-59051-342-2. Процитовано 30 березня 2011.
Krummel MF, Allison JP (August 1995). CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. The Journal of Experimental Medicine. 182 (2): 459—465. doi:10.1084/jem.182.2.459. PMC 2192127. PMID 7543139.
Walunas TL, Bakker CY, Bluestone JA (June 1996). CTLA-4 ligation blocks CD28-dependent T cell activation. The Journal of Experimental Medicine. 183 (6): 2541—2550. doi:10.1084/jem.183.6.2541. PMC 2192609. PMID 8676075.

biocentury.com

Yervoy, ipilimumab (BMS-734016) - Product Profile - BioCentury. BioCentury Online Intelligence. BioCentury Publications. Процитовано 11 серпня 2016.

bms.com

packageinserts.bms.com

Yervoy (ipilimumab) [package insert] (PDF). Princeton, NJ: Bristol-Myers Squibb Company; Dec 2013. Архів оригіналу (PDF) за 6 February 2015. Процитовано 29 жовтня 2014.

books.google.com

2010 oncology nursing drug handbook. Jones & Bartlett Learning. 11 грудня 2009. с. 1–. ISBN 978-0-7637-8124-8. Процитовано 30 березня 2011.
Macromolecular Anticancer Therapeutics. Springer. 1 червня 2009. с. 522–. ISBN 978-1-4419-0506-2. Процитовано 30 березня 2011.
Therapeutic Monoclonal Antibodies: From Bench to Clinic. John Wiley and Sons. 8 вересня 2009. с. 134–. ISBN 978-0-470-11791-0. Процитовано 30 березня 2011.

doi.org

Maverakis E, Cornelius LA, Bowen GM, Phan T, Patel FB, Fitzmaurice S, He Y, Burrall B, Duong C, Kloxin AM, Sultani H, Wilken R, Martinez SR, Patel F (May 2015). Metastatic melanoma - a review of current and future treatment options. Acta Dermato-Venereologica. 95 (5): 516—524. doi:10.2340/00015555-2035. PMID 25520039. {{cite journal}}: Недійсний |displayauthors=6 (довідка)
Johnson DB, Peng C, Sosman JA (March 2015). Nivolumab in melanoma: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology. 7 (2): 97—106. doi:10.1177/1758834014567469. PMC 4346215. PMID 25755682.
Bellaguarda E, Hanauer S (February 2020). Checkpoint Inhibitor-Induced Colitis. The American Journal of Gastroenterology. 115 (2): 202—210. doi:10.14309/ajg.0000000000000497. PMID 31922959.
Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J (April 2013). Hepatotoxicity with combination of vemurafenib and ipilimumab. The New England Journal of Medicine. 368 (14): 1365—1366. doi:10.1056/NEJMc1302338. PMID 23550685.
Ribas A (June 2012). Tumor immunotherapy directed at PD-1. The New England Journal of Medicine. 366 (26): 2517—2519. doi:10.1056/nejme1205943. PMID 22658126.
Tarhini AA, Iqbal F (June 2010). CTLA-4 blockade: therapeutic potential in cancer treatments. OncoTargets and Therapy. 3: 15—25. doi:10.2147/ott.s4833. PMC 2895779. PMID 20616954.{{cite journal}}: Обслуговування CS1: Сторінки із непозначеним DOI з безкоштовним доступом (посилання)
Robert C, Ghiringhelli F (August 2009). What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?. The Oncologist. 14 (8): 848—861. doi:10.1634/theoncologist.2009-0028. PMID 19648604.
Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, Golstein P (Jul 1987). A new member of the immunoglobulin superfamily--CTLA-4. Nature. 328 (6127): 267—270. Bibcode:1987Natur.328..267B. doi:10.1038/328267a0. PMID 3496540.
Harper K, Balzano C, Rouvier E, Mattéi MG, Luciani MF, Golstein P (August 1991). CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. Journal of Immunology. 147 (3): 1037—1044. doi:10.4049/jimmunol.147.3.1037. PMID 1713603.
Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP (April 1992). CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature. 356 (6370): 607—609. Bibcode:1992Natur.356..607H. doi:10.1038/356607a0. PMID 1313950.
Krummel MF, Allison JP (August 1995). CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. The Journal of Experimental Medicine. 182 (2): 459—465. doi:10.1084/jem.182.2.459. PMC 2192127. PMID 7543139.
Krummel MF, Sullivan TJ, Allison JP (April 1996). Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. International Immunology. 8 (4): 519—523. doi:10.1093/intimm/8.4.519. PMID 8671638.
Leach DR, Krummel MF, Allison JP (March 1996). Enhancement of antitumor immunity by CTLA-4 blockade. Science. 271 (5256): 1734—1736. Bibcode:1996Sci...271.1734L. doi:10.1126/science.271.5256.1734. PMID 8596936.
Walunas TL, Bakker CY, Bluestone JA (June 1996). CTLA-4 ligation blocks CD28-dependent T cell activation. The Journal of Experimental Medicine. 183 (6): 2541—2550. doi:10.1084/jem.183.6.2541. PMC 2192609. PMID 8676075.
Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA (August 1994). CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1 (5): 405—413. doi:10.1016/1074-7613(94)90071-x. PMID 7882171. {{cite journal}}: Недійсний |displayauthors=6 (довідка)
Kearney ER, Walunas TL, Karr RW, Morton PA, Loh DY, Bluestone JA, Jenkins MK (August 1995). Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. Journal of Immunology. 155 (3): 1032—1036. doi:10.4049/jimmunol.155.3.1032. PMID 7543510.
Linsley PS, Greene JL, Tan P, Bradshaw J, Ledbetter JA, Anasetti C, Damle NK (December 1992). Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. The Journal of Experimental Medicine. 176 (6): 1595—1604. doi:10.1084/jem.176.6.1595. PMC 2119471. PMID 1334116.

europa.eu

ema.europa.eu

Yervoy Annex I: Summary of Product Characteristics (PDF). Архів оригіналу (PDF) за 20 грудня 2014. Процитовано 2 листопада 2014. [Архівовано 2014-12-20 у Wayback Machine.]

fda.gov

FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma. U.S. Food and Drug Administration (FDA). 16 квітня 2018. Процитовано 2 жовтня 2020.
FDA grants accelerated approval to ipilimumab for MSI-H or dMMR metastatic colorectal cancer. U.S. Food and Drug Administration (FDA). 10 липня 2018. Процитовано 2 жовтня 2020.
FDA grants accelerated approval to nivolumab and ipilimumab combination for hepatocellular carcinoma. U.S. Food and Drug Administration (FDA). 10 березня 2020. Процитовано 2 жовтня 2020.
FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression ≥1%). U.S. Food and Drug Administration (FDA). 15 травня 2020. Процитовано 2 жовтня 2020.
FDA approves nivolumab plus ipilimumab and chemotherapy for first-line treatment of metastatic NSCLC. U.S. Food and Drug Administration (FDA). 26 травня 2020. Процитовано 2 жовтня 2020.

gene.com

Zelboraf (vemurafenib) [package insert] (PDF). South San Francisco, CA: Genentech USA, Inc.; March 2013. Процитовано 29 жовтня 2014.

harvard.edu

ui.adsabs.harvard.edu

Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, Golstein P (Jul 1987). A new member of the immunoglobulin superfamily--CTLA-4. Nature. 328 (6127): 267—270. Bibcode:1987Natur.328..267B. doi:10.1038/328267a0. PMID 3496540.
Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP (April 1992). CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature. 356 (6370): 607—609. Bibcode:1992Natur.356..607H. doi:10.1038/356607a0. PMID 1313950.
Leach DR, Krummel MF, Allison JP (March 1996). Enhancement of antitumor immunity by CTLA-4 blockade. Science. 271 (5256): 1734—1736. Bibcode:1996Sci...271.1734L. doi:10.1126/science.271.5256.1734. PMID 8596936.

medscape.com

Two Cases of Myasthenia Gravis Seen With Ipilimumab. 29 квітня 2014.

nih.gov

pubmed.ncbi.nlm.nih.gov

Maverakis E, Cornelius LA, Bowen GM, Phan T, Patel FB, Fitzmaurice S, He Y, Burrall B, Duong C, Kloxin AM, Sultani H, Wilken R, Martinez SR, Patel F (May 2015). Metastatic melanoma - a review of current and future treatment options. Acta Dermato-Venereologica. 95 (5): 516—524. doi:10.2340/00015555-2035. PMID 25520039. {{cite journal}}: Недійсний |displayauthors=6 (довідка)
Johnson DB, Peng C, Sosman JA (March 2015). Nivolumab in melanoma: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology. 7 (2): 97—106. doi:10.1177/1758834014567469. PMC 4346215. PMID 25755682.
Bellaguarda E, Hanauer S (February 2020). Checkpoint Inhibitor-Induced Colitis. The American Journal of Gastroenterology. 115 (2): 202—210. doi:10.14309/ajg.0000000000000497. PMID 31922959.
Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J (April 2013). Hepatotoxicity with combination of vemurafenib and ipilimumab. The New England Journal of Medicine. 368 (14): 1365—1366. doi:10.1056/NEJMc1302338. PMID 23550685.
Ribas A (June 2012). Tumor immunotherapy directed at PD-1. The New England Journal of Medicine. 366 (26): 2517—2519. doi:10.1056/nejme1205943. PMID 22658126.
Tarhini AA, Iqbal F (June 2010). CTLA-4 blockade: therapeutic potential in cancer treatments. OncoTargets and Therapy. 3: 15—25. doi:10.2147/ott.s4833. PMC 2895779. PMID 20616954.{{cite journal}}: Обслуговування CS1: Сторінки із непозначеним DOI з безкоштовним доступом (посилання)
Robert C, Ghiringhelli F (August 2009). What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?. The Oncologist. 14 (8): 848—861. doi:10.1634/theoncologist.2009-0028. PMID 19648604.
Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, Golstein P (Jul 1987). A new member of the immunoglobulin superfamily--CTLA-4. Nature. 328 (6127): 267—270. Bibcode:1987Natur.328..267B. doi:10.1038/328267a0. PMID 3496540.
Harper K, Balzano C, Rouvier E, Mattéi MG, Luciani MF, Golstein P (August 1991). CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. Journal of Immunology. 147 (3): 1037—1044. doi:10.4049/jimmunol.147.3.1037. PMID 1713603.
Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP (April 1992). CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature. 356 (6370): 607—609. Bibcode:1992Natur.356..607H. doi:10.1038/356607a0. PMID 1313950.
Krummel MF, Allison JP (August 1995). CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. The Journal of Experimental Medicine. 182 (2): 459—465. doi:10.1084/jem.182.2.459. PMC 2192127. PMID 7543139.
Krummel MF, Sullivan TJ, Allison JP (April 1996). Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. International Immunology. 8 (4): 519—523. doi:10.1093/intimm/8.4.519. PMID 8671638.
Leach DR, Krummel MF, Allison JP (March 1996). Enhancement of antitumor immunity by CTLA-4 blockade. Science. 271 (5256): 1734—1736. Bibcode:1996Sci...271.1734L. doi:10.1126/science.271.5256.1734. PMID 8596936.
Walunas TL, Bakker CY, Bluestone JA (June 1996). CTLA-4 ligation blocks CD28-dependent T cell activation. The Journal of Experimental Medicine. 183 (6): 2541—2550. doi:10.1084/jem.183.6.2541. PMC 2192609. PMID 8676075.
Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA (August 1994). CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1 (5): 405—413. doi:10.1016/1074-7613(94)90071-x. PMID 7882171. {{cite journal}}: Недійсний |displayauthors=6 (довідка)
Kearney ER, Walunas TL, Karr RW, Morton PA, Loh DY, Bluestone JA, Jenkins MK (August 1995). Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. Journal of Immunology. 155 (3): 1032—1036. doi:10.4049/jimmunol.155.3.1032. PMID 7543510.
Linsley PS, Greene JL, Tan P, Bradshaw J, Ledbetter JA, Anasetti C, Damle NK (December 1992). Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. The Journal of Experimental Medicine. 176 (6): 1595—1604. doi:10.1084/jem.176.6.1595. PMC 2119471. PMID 1334116.

ncbi.nlm.nih.gov

Johnson DB, Peng C, Sosman JA (March 2015). Nivolumab in melanoma: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology. 7 (2): 97—106. doi:10.1177/1758834014567469. PMC 4346215. PMID 25755682.
Tarhini AA, Iqbal F (June 2010). CTLA-4 blockade: therapeutic potential in cancer treatments. OncoTargets and Therapy. 3: 15—25. doi:10.2147/ott.s4833. PMC 2895779. PMID 20616954.{{cite journal}}: Обслуговування CS1: Сторінки із непозначеним DOI з безкоштовним доступом (посилання)
Krummel MF, Allison JP (August 1995). CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. The Journal of Experimental Medicine. 182 (2): 459—465. doi:10.1084/jem.182.2.459. PMC 2192127. PMID 7543139.
Walunas TL, Bakker CY, Bluestone JA (June 1996). CTLA-4 ligation blocks CD28-dependent T cell activation. The Journal of Experimental Medicine. 183 (6): 2541—2550. doi:10.1084/jem.183.6.2541. PMC 2192609. PMID 8676075.
Linsley PS, Greene JL, Tan P, Bradshaw J, Ledbetter JA, Anasetti C, Damle NK (December 1992). Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. The Journal of Experimental Medicine. 176 (6): 1595—1604. doi:10.1084/jem.176.6.1595. PMC 2119471. PMID 1334116.

sanofi.com.au

products.sanofi.com.au

Arava (leflunomide) [package insert] (PDF). Australia: Sanofi-Aventis, July 2014. Архів оригіналу (PDF) за 2 November 2014. Процитовано 2 листопада 2014. [Архівовано 2014-11-02 у Wayback Machine.]

web.archive.org

USAN. STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL - ipilimumab (Пресреліз). American Medical Association (AMA). Архів оригіналу за 23 лютого 2016. Процитовано 12 січня 2013.
Arava (leflunomide) [package insert] (PDF). Australia: Sanofi-Aventis, July 2014. Архів оригіналу (PDF) за 2 November 2014. Процитовано 2 листопада 2014. [Архівовано 2014-11-02 у Wayback Machine.]
Yervoy (ipilimumab) [package insert] (PDF). Princeton, NJ: Bristol-Myers Squibb Company; Dec 2013. Архів оригіналу (PDF) за 6 February 2015. Процитовано 29 жовтня 2014.
Yervoy Annex I: Summary of Product Characteristics (PDF). Архів оригіналу (PDF) за 20 грудня 2014. Процитовано 2 листопада 2014. [Архівовано 2014-12-20 у Wayback Machine.]